查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853288

细胞和基因治疗製造服务市场（按服务类型、技术类型、治疗领域、应用和最终用户划分）—2025-2032年全球预测

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞和基因治疗製造服务市场将成长至 669.2 亿美元，复合年增长率为 16.30%。

关键市场统计数据
基准年2024年 199.8亿美元
预计年份：2025年 230.6亿美元
预测年份 2032 669.2亿美元
复合年增长率（%） 16.30%

一篇权威的介绍文章，阐述了细胞和基因治疗生产服务为何对临床成功和商业化策略至关重要。

细胞和基因治疗生产服务已从零散的先导计画发展成为先进治疗药物开发中具有战略意义的重要组成部分。如今，卓越的生产能力不仅决定临床应用的速度，也决定复杂生技药品的商业可行性。本执行摘要整合了营运、技术、监管和商业等各方面的动态因素，这些因素正在改变您制定生产策略和选择外部合作伙伴的方式。

在整个价值链中，分析方法的准确性、供应链的可靠性和製程开发的稳健性已成为关键的竞争优势。製造商和服务供应商必须同时应对生物製药的复杂性、严格的监管以及日益全球化的供应商群体。因此，企业主管正优先投资于平台技术、品质系统和整合服务，以降低技术风险并加速临床试验进程。

以下各节将探讨结构性变化、近期贸易政策介入的影响、细分市场的具体动态、区域差异、企业策略倡议以及对产业领导者的实用建议。每个部分都组装为评估製造伙伴关係、能力投资和能力发展倡议的组织提供清晰的决策路径。

技术进步、营运数位化和监管预期如何融合，正迫使细胞和基因治疗製造服务产业进行策略转型

该产业正经历变革时期，这场变革从根本上改变了治疗方法的研发和生产方式。基因编辑技术的进步、病毒和非病毒载体应用范围的扩大以及精密的分析工具的出现，提高了人们对药物可重复性和效力的技术期望。同时，基于平台的製程开发和模组化设施设计的转变，使得在保证产品品质和符合法规要求的前提下，能够更快地扩大生产规模。

在营运方面，数位化和自动化正在降低关键工作流程中的变异性和对劳动力的依赖性。机器学习和流程分析越来越多地应用于进程内控制和批次放行决策，从而提高批次一致性并加快放行速度。同时，为了接近性患者以及对温度敏感型物料输送的物流要求，分散式和混合製造模式正日益受到青睐。

监管参与也在不断演变，监管机构更加重视生命週期品管、可比较性和长期安全性监测。这促使研发人员、受託製造和监管机构之间需要更紧密的合作，尤其是在研发早期阶段。此外，策略资本正流入能够提供涵盖载体生产、製程开发和GMP生产等一体化服务的专业合约研发受託製造厂商（ CDMO），这凸显了市场向端到端提案转变的趋势，从而降低了研发专案的风险。

了解美国2025年关税对全球供应链和製造业韧性的多层次营运和策略影响

2025年实施的新关税进一步加剧了本已复杂的细胞和基因治疗生产全球供应链的复杂性。进口关税及相关贸易措施提高了许多进口原料、专用试剂和生产设备的相对成本和前置作业时间。因此，各公司正在重新审视其供应商组合和筹资策略，以降低跨境价格波动带来的风险。

为此，许多开发商和服务供应商正在加快关键投入品的在地化进程，并投资于国内供应商的资格认证，以确保供应的连续性。这些努力通常需要同时在品质保证和法规遵循方面进行投资，以确保替代方案符合严格的GMP要求。因此，采购团队正在投入更多资源用于供应商资格认证、审核准备以及锁定品质和交付条款的长期合约机制。

契约製造製造商和技术供应商正在调整其商业模式，透过替代采购、远期采购和合约定价条款来应对关税带来的衝击。此外，贸易措施也强化了区域製造地的策略合理性。区域邻近性能够降低关税的影响，缩短通路，并加强对区域法规结构的遵守。总而言之，关税的累积影响不仅体现在财务方面，也体现在结构方面，迫使企业重新思考如何组织其製造网络，以增强韧性并符合监管要求。

深度细分洞察揭示了服务类型、技术平台、治疗重点、用例和最终用户需求如何影响服务提供者的定位。

细分市场分析揭示了不同服务类型、技术平台、治疗适应症、应用场景和最终用户类别之间的差异化需求。分析和品管服务、细胞库服务、咨询服务、灌装和包装服务、GMP生产服务、製程开发服务、法规支援服务、供应链和物流服务、技术转移服务以及载体生产服务等产品类型，各自面临独特的能力和产能需求。能够提供将载体生产与强大的分析和法规支援相结合的整合服务套件的供应商，对寻求透过单一供应商降低风险的开发商更具吸引力。相反，专注于特定服务领域的专业化供应商，可以透过提供卓越的技术深度和客製化解决方案来获得高端市场定位。

依技术类型划分，可以区分参与基因编辑和载体研发的机构。在基因编辑领域，CRISPR/Cas9、转录活化因子样效应核酸酶（TRAEN）和锌指核酸酶（ZFNA）等技术各自需要不同的製程开发路径和监管文件。非病毒载体包括阳离子脂质体、几丁聚醣基载体、树状聚合物、无机奈米颗粒、脂质体、裸露DNA/RNA、肽基载体和聚合物载体，每种载体都有不同的製剂和递送要求。病毒载体包括腺结合病毒载体、腺病毒载体、单纯疱疹病毒载体和逆转录病毒载体，这些载体需要专门的生物安全防护、生产平台和效力检测。能够展现跨平台专业知识和快速技术转移能力的公司，将更有利于抓住新的专案需求。

治疗领域细分区分了心血管疾病、感染疾病、单药疗法和肿瘤的研发路径。在心血管疾病领域，针对冠状动脉疾病和心臟衰竭的项目与针对B型肝炎和爱滋病毒的感染疾病项目相比，其安全性和发行策略有所不同。囊肿纤维化、血友病和镰状细胞贫血等单一疗法计画强调治疗目的和长期随访，因此对载体的生物分布和持久性有着严格的控制。肿瘤项目分为血液系统恶性肿瘤和固态肿瘤，其给药方案和细胞类型各不相同，导致生产规模和放行标准也存在差异。

基于应用领域的细分区分了临床生产和商业生产。临床生产强调小规模生产的灵活性、快速切换和可重复性，而商业生产则需要强大的规模、成本效益和检验的高通量分析。最终用户细分揭示了委外研发机构 ( CRO)、医院和诊所、製药和生物技术公司以及研究和学术机构之间不同的购买行为和预期能力。 CRO 优先考虑快速週转和符合监管要求，医院和诊所寻求以患者为中心的本地化解决方案，製药和生物技术公司重视从开发到商业化的一体化路径，而研究机构则重视平台存取和技术转移支援。了解这些细分领域的交集，有助于供应商和申办者制定符合自身技术优势、符合买方优先事项和治疗需求的提案。

区域对比分析展示了美洲、欧洲、中东和非洲以及亚太地区各自如何影响战略製造和伙伴关係决策。

区域动态对企业选择在何处投资产能、与承包商合作以及寻找专业人才有显着影响。在美洲，由契约製造、学术机构和新创公司组成的密集生态系统为快速转化路径提供了支持。这种环境，加上毗邻庞大的患者群体和资本市场的优势，鼓励企业采取垂直整合策略并投资于载体生产能力。

欧洲、中东和非洲呈现异质性格局，卓越中心集中在那些监管环境有利且生物製造基础设施先进的国家。在欧洲，跨境合作有助于获取技能娴熟的劳动力和分析专长，但分散的报销体系和区域性监管差异要求制定量身定制的打入市场策略。在中东和非洲部分地区，战略伙伴关係和知识转移倡议正在兴起，这些计划通常由政府主导的能力建设项目推动。

亚太地区以其快速扩张的製造能力、对生物技术生态系统的大量公共和私人投资以及日益增多的专业製造服务提供者而脱颖而出。多个司法管辖区针对先进治疗方法的监管路径不断完善，以及该地区的供应链优势（尤其是在试剂和设备製造方面），正促使跨国开发商将亚太地区的生产纳入其全球策略。每个地区的监管环境、人才储备和供应链结构都应作为决策依据，用于决定设施选址、外包哪些服务以及如何建立商业伙伴关係以确保长期稳健发展。

决定哪些供应商订单哪些专案并建立哪些伙伴关係的策略性企业行为和竞争动态

企业行为揭示了一个市场格局：策略差异化源自于能力广度、技术专长和伙伴关係模式。领先的服务供应商整合了载体生产、製程开发和分析平台的投资，从而提供从早期开发到商业化的一体化路径。这种能力减少了技术交接环节，降低了专案风险，并吸引了寻求可预测时间表的赞助商。同时，专注于高复杂性细分领域（例如AAV生产、非病毒递送平台和高级分析）的专业公司，凭藉可重复的技术性能和深厚的监管知识，赢得了高额的委託项目。

策略联盟和併购是快速获取自身缺失能力的常用机制，尤其是在企业寻求从提供服务转型为拥有平台的过程中。外包模式也不断多元化。一些製药和生技公司寻求共同投资建造专用设施以确保产能，而有些公司则倾向于灵活的按服务收费协议。品质系统、监管记录和已证实的技术转移经验已成为重要的合约标准。此外，拥有数位化品管系统、完善的批次记录可追溯性和先进的环境监测技术的公司，凭藉更低的偏差率和更快的监管检查速度，正在脱颖而出。

竞争格局也凸显了透明的风险分担协议、基于里程碑的定价以及能够协调赞助商和製造商之间奖励的混合商业模式的重要性。此外，越来越多的公司正在投资永续製造实践和循环供应链计划，这展现了其长期的营运纪律，并可能影响具有环保意识的赞助商的采购决策。

为产业领导者提供实际的高影响力建议，以加强供应链、加速技术转移并确保製造营运面向未来。

领导者应优先采取一系列切实可行的措施来降低风险、加快研发进度并保障净利率。首先，应实现关键试剂和设备来源多元化，同时寻找二级供应商并建立长期合约保障机制，以降低关税和供应链中断的影响。此外，还应投资建立强大的分析能力和标准化检测方法，以缩短技术转移过程中的资格确认时间，并支援快速提交监管文件。

第二，采用模组化、平台化的流程架构，实现从临床到商业化的无缝扩展。这包括标准化单元操作、统一文件以及引入数位化流程控制以降低变异性。第三，寻求兼具技术深度和商业性覆盖范围的策略伙伴关係关係。将载体生产与下游填充、包装和分析环节集中进行，可显着降低交接风险并缩短整体专案週期。

第四，从研发初期就积极与监理机关沟通，合作制定可比性策略、效力检测法和长期安全性监测计画。第五，透过有针对性的技能提升计划，提升员工能力，并专注于GMP最佳实践、进阶分析和设施自动化。第六，在製定区域布局决策时，应考虑关税影响、人才供应情况以及与临床试验中心的接近性。最后，将永续性指标纳入设施规划和供应商选择，以降低长期营运风险并满足相关人员的新期望。

一种透明的混合研究途径，结合了专家访谈、能力映射和情境检验，以支持策略洞察。

这些研究成果基于一种混合方法，结合了专家访谈、技术评估和文件分析。主要资料来源包括对申办者和医疗服务提供机构的高级製造领导者、品管主管和监管专家进行的结构化访谈，从而深入观点营运限制和策略重点。这些定性见解与监管指南的技术审查、同行评审文献和公开资讯进行三角验证，以检验有关技术趋势和能力的论点。

我们开展了一项详细的能力映射工作，以评估服务供应商在载体生产、製程开发、GMP生产、分析和法规支援等方面的能力。我们使用平台成熟度、过去的可比性研究和商业规模示范等标准来评估技术的成熟度和可转移性。供应链弹性评估则考虑了供应商集中度、地理分布和前置作业时间敏感度。

数据验证包括与第三方技术报告和观察到的监管结果进行交叉核对。基于情境的分析考虑了在各种贸易和生产能力条件下製造网路和供应商策略的替代配置。调查方法强调透明度和可重复性。研究资料包中包含了访谈通讯协定、产能评估纳入标准以及情境参数的依据，并提供给了买方。

本文简要总结了为何生产能力、监管合规性和供应链韧性是成功开发先进疗法的关键驱动因素。

细胞和基因治疗製造服务产业正处于曲折点，技术进步、不断变化的监管环境以及地缘政治主导正在交汇融合，共同塑造战略选择。能够建立模组化、数据驱动流程并确保供应商网路多元化的服务提供者和申办方，将更有能力应对关税带来的不利影响和区域营运的复杂性。儘早与监管机构沟通并建立可验证的品质体系，仍然是成功进行技术转移和商业化的必要前提。

各组织必须平衡规模、灵活性和风险降低这三者之间的相互衝突的需求。选择整合平台策略和目标明确的伙伴关係关係的公司可以加快专案进度并减少专案损耗，而专注于特定领域的专家对于应对高度复杂的技术挑战仍然至关重要。最终，在製造卓越性日益与治疗成功挂钩的市场中，对流程标准化、劳动力能力和区域韧性的规划投资将决定企业的竞争力。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合封闭式自动化生物反应器系统进行大规模CAR-T细胞生产，以提高重复性
  • 应用数位双胞胎和製程分析技术对基因治疗生产进行即时监控
  • 利用模组化GMP套件扩展分散式生产网络，以加速区域临床供应。
  • 病毒载体及细胞基材组成优质原料及供应链可追溯性的标准化
  • 采用一次性生产平台，最大限度地减少交叉污染，并提高设施的灵活性。
  • CDMO与学术中心合作开发现成的同种异体细胞疗法产品线
  • 关于先进疗法药物疗效测试和可比较性的监管协调工作
  • 投资先进的病毒载体纯化技术，以提高产量并减少下游瓶颈
  • 利用人工智慧驱动的流程优化实现细胞和基因治疗生产中的预测性维护和产量比率提升
  • 制定冷冻保存通讯协定和供应链物流，以支持活细胞疗法的全球分销

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 细胞和基因治疗製造服务市场（按服务类型划分）

  • 分析和品管服务
  • 细胞银行服务
  • 咨询服务
  • 灌装和精加工服务
  • GMP生产服务
  • 流程开发服务
  • 监管支援服务
  • 供应炼和物流服务
  • 技术转移服务
  • 向量图创建服务

9. 按技术类型分類的细胞和基因治疗製造服务市场

  • 基因编辑
    • CRISPR/Cas9
    • 转录活化因子样效应核酸酶
    • 锌指核酸酶
  • 向量
    • 非病毒载体
      • 阳离子脂质
      • 基于几丁聚醣的载体
      • 树状聚合物
      • 无机奈米粒子
      • 脂质体
      • 裸露的DNA/RNA
      • 基于胜肽的载体
      • 聚合物载体
    • 病毒载体
      • 腺结合病毒（AAV）载体
      • 腺病毒载体
      • 单纯疱疹病毒（HSV）载体
      • 逆转录病毒载体

第十章 按治疗领域分類的细胞和基因治疗製造服务市场

  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 单基因疾病
    • 囊肿纤维化
    • 血友病
    • 镰状细胞贫血症
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤

第十一章 细胞与基因疗法製造服务市场（按应用领域划分）

  • 临床生产
  • 商业製造

第十二章 细胞和基因治疗製造服务市场（按最终用户划分）

  • 合约研究组织
  • 医院和诊所
  • 製药和生物技术公司
  • 研究和学术机构

13. 各区域细胞及基因治疗製造服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞与基因治疗製造服务市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细胞与基因治疗製造服务市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Advanced BioScience Laboratories, Inc. by Institut Merieux
    • AGC Biologics
    • AmplifyBio
    • Bio-Techne Corporation
    • CH Boehringer Sohn AG & Co. KG
    • Catalent, Inc.
    • Cell Therapies Pty Ltd.
    • Cell-Easy
    • Charles River Laboratories International, Inc.
    • Danaher Corporation
    • eXmoor Pharma Concepts Limited
    • FUJIFILM Diosynth Biotechnologies
    • Genezen Laboratories, Inc.
    • Laboratory Corporation of America Holdings
    • Lonza Group AG
    • Merck KGaA
    • Miltenyi Biotec BV & Co. KG
    • Minaris Regenerative Medicine GmbH by Resonac Corporation
    • Nikon Corporation
    • Novartis AG
    • Oxford Biomedica PLC
    • ProPharma Group Holdings, LLC
    • Recipharm AB
    • Samsung Biologics Co., Ltd.
    • SGS SA
    • STEMCELL Technologies Inc.
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • uBriGene Biosciences Inc.
    • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market is projected to grow by USD 66.92 billion at a CAGR of 16.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 19.98 billion
Estimated Year [2025] USD 23.06 billion
Forecast Year [2032] USD 66.92 billion
CAGR (%) 16.30%

An authoritative introduction framing why manufacturing services for cell and gene therapies are now pivotal to clinical success and commercialization strategies

The cell and gene therapy manufacturing services landscape has matured from fragmented pilot projects to a strategically critical component of advanced therapeutics development. Manufacturing excellence now determines not only the speed of clinical translation but also the viability of commercialization for complex biologics. This executive summary synthesizes operational, technological, regulatory, and commercial dynamics that are reshaping how organizations design manufacturing strategies and select external partners.

Across the value chain, precision in analytical methods, reliability in supply chains, and robustness in process development have become decisive competitive differentiators. Manufacturers and service providers must simultaneously manage biologic complexity, regulatory stringency, and an increasingly globalized supplier base. Consequently, senior leaders are prioritizing investments in platform technologies, quality systems, and integrated services that reduce technical risk while accelerating time to clinic.

The following sections examine structural shifts, the implications of recent trade policy interventions, segmentation-specific dynamics, regional contrasts, corporate strategic behaviors, and pragmatic recommendations for industry leaders. Each element is framed to support clear decision-making pathways for organizations evaluating manufacturing partnerships, capacity investments, or capability development initiatives.

How converging technical advances, operational digitization, and regulatory expectations are forcing strategic reinvention across cell and gene therapy manufacturing services

The industry is undergoing transformative shifts that are altering the fundamentals of how therapies are developed and manufactured. Advances in gene editing, expanding use cases for viral and non-viral vectors, and refined analytical tools are raising technical expectations for reproducibility and potency. In tandem, a move toward platform-based process development and modular facility designs is enabling faster scale-up while preserving product quality and regulatory compliance.

Operationally, digitization and automation are reducing variability and labor dependence in critical workflows. Machine learning and process analytics are increasingly applied to in-process controls and batch release decisions, improving lot consistency and accelerating release timelines. At the same time, decentralized and hybrid manufacturing models are gaining traction, driven by the need for geographic proximity to patients and by logistical imperatives for temperature-sensitive material handling.

Regulatory engagement has also evolved; regulators are placing greater emphasis on lifecycle quality management, comparability, and long-term safety monitoring. This has prompted closer collaboration between developers, contract manufacturers, and regulators earlier in development. Finally, strategic capital is flowing into specialized contract development and manufacturing organizations that can offer integrated services across vector production, process development, and GMP manufacturing, underscoring a market-wide shift toward end-to-end propositions that de-risk development programs.

Understanding the layered operational and strategic consequences of the 2025 United States tariff measures on global supply chains and manufacturing resilience

Recent tariff actions introduced in 2025 have created a complex overlay on an already intricate global supply chain for cell and gene therapy manufacturing. Import duties and related trade measures have increased the relative cost and lead time of many imported raw materials, specialized reagents, and manufacturing equipment. As a result, organizations are reassessing supplier portfolios and procurement strategies to mitigate exposure to cross-border pricing volatility.

In response, many developers and service providers have accelerated localization of critical inputs and invested in qualifying domestic suppliers to secure continuity of supply. These efforts often require parallel investments in quality assurance and regulatory alignment to ensure substitutes meet stringent GMP expectations. Consequently, procurement teams are devoting more resources to supplier qualification, audit readiness, and long-term contracting mechanisms that lock in quality and delivery terms.

Contract manufacturers and technology vendors are adjusting commercial models to absorb some tariff-related friction through alternative sourcing, forward purchasing, and contractual pricing clauses. Moreover, trade measures have intensified the strategic rationale for regional manufacturing footprints, where proximity reduces tariff exposure, shortens distribution pathways, and enhances compliance with local regulatory frameworks. Taken together, the cumulative impact of tariffs is not only financial but also structural, prompting organizations to rethink how manufacturing networks should be organized for resilience and regulatory congruence.

Deep segmentation insights that reveal how distinct service types, technology platforms, therapeutic focuses, applications, and end-user needs shape provider positioning

Segmentation analysis reveals differentiated imperatives across service types, technology platforms, therapeutic indications, application contexts, and end-user categories. Service types such as Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services each face unique capability and capacity demands. Providers offering integrated suites that combine vector production with robust analytics and regulatory support achieve greater appeal to developers seeking single-vendor risk reduction. Conversely, highly specialized providers that concentrate on a narrow set of services can secure premium positioning by delivering superior technical depth and bespoke solutions.

Technology type segmentation differentiates organizations working in Gene Editing and Vectors. Within Gene Editing, approaches such as CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases require distinct process development pathways and regulatory dossiers. Vector technologies split into Non-Viral and Viral Vectors; Non-Viral Vectors encompass cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, each with divergent formulation and delivery considerations. Viral Vectors include adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, and these necessitate specialized containment, production platforms, and potency assays. Firms that can demonstrate cross-platform expertise or rapid transferability between these technology types are better positioned to capture emerging program demand.

Therapeutic area segmentation distinguishes development pathways across cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Within cardiovascular diseases, programs focused on coronary artery disease and heart failure require distinct safety and delivery strategies compared with infectious disease programs targeting hepatitis B or HIV. Monogenic disorder efforts such as cystic fibrosis, hemophilia, and sickle cell anemia emphasize curative intent and long-term follow-up, imposing rigorous controls on vector biodistribution and persistence. Oncology programs, split between hematological malignancies and solid tumors, demand divergent manufacturing scales and release criteria due to differing dosing paradigms and cell types.

Application-based segmentation differentiates clinical manufacturing from commercial manufacturing. Clinical manufacturing emphasizes flexibility, rapid changeover, and small-batch reproducibility, while commercial manufacturing demands robust scale, cost efficiencies, and validated high-throughput analytics. End-user segmentation highlights the varied buying behaviors and capability expectations of contract research organizations, hospitals & clinics, pharmaceutical & biotech companies, and research institutes & academic institutions. CROs prioritize rapid turnaround and regulatory alignment, hospitals and clinics seek localized solutions for patient-centric delivery, pharmaceutical and biotech companies emphasize integrated development-to-commercial pathways, and research institutes focus on platform access and technology transfer support. Understanding these intersecting segmentation layers enables providers and sponsors to tailor propositions that align technical strengths with buyer priorities and therapeutic requirements.

Comparative regional intelligence explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape strategic manufacturing and partnership decisions

Regional dynamics materially influence where organizations choose to invest in capacity, partner with contractors, and locate specialized capabilities. In the Americas, a dense ecosystem of contract manufacturers, academic spinouts, and venture-backed developers supports rapid translational pathways, while regulatory agencies are offering increasingly mature guidance frameworks for advanced therapies. This environment encourages vertically integrated strategies and investments in vector production capacity, given the proximity to large patient populations and capital markets.

Europe, the Middle East & Africa present a heterogeneous landscape, with centers of excellence clustered in countries that combine favorable regulatory clarity with advanced biomanufacturing infrastructure. Cross-border collaborations within Europe facilitate access to skilled labor and analytic expertise, yet fragmented reimbursement and localized regulatory nuances require tailored market entry strategies. In parts of the Middle East and Africa, strategic partnerships and knowledge transfer initiatives are emerging, often driven by government-led capacity-building programs.

Asia-Pacific stands out for rapid expansion of manufacturing capacity, significant public and private investment in biotech ecosystems, and a growing cadre of specialized manufacturing service providers. Regulatory pathways in several jurisdictions are evolving to accommodate advanced therapies, and regional supply chain advantages-particularly in reagents and equipment manufacturing-are prompting multinational developers to consider Asia-Pacific-based production as part of global strategies. Each region's regulatory posture, talent availability, and supply chain topology should inform decisions about where to site facilities, which services to insource, and how to structure commercial partnerships for long-term resilience.

Strategic company behaviors and competitive dynamics that determine which providers are winning mandates and how partnerships are being structured

Corporate behaviors reveal a market in which strategic differentiation emerges from capability breadth, technological specialization, and partnership models. Leading service providers are combining investments in vector production, process development, and analytical platforms to offer integrated pathways from early development through commercialization. These capabilities reduce technical handoffs and lower program risk, attracting sponsors seeking predictable timelines. At the same time, specialized firms that focus on high-complexity niches-such as AAV manufacturing, non-viral delivery platforms, or advanced analytics-are capturing premium mandates by demonstrating reproducible technical performance and deep regulatory know-how.

Strategic alliances and M&A activity are common mechanisms for acquiring missing capabilities rapidly, particularly when organizations aim to move from service provision to platform ownership. Outsourcing models continue to diversify; some pharmaceutical and biotech companies pursue co-investment in dedicated facilities to secure capacity, while others prefer flexible, fee-for-service engagements. Quality systems, regulatory track records, and demonstrated technology transfer experience are decisive contracting criteria. Additionally, firms that adopt digital quality management systems, robust batch record traceability, and advanced environmental monitoring differentiate themselves through lower deviation rates and faster regulatory inspections.

The competitive landscape also values transparent risk-sharing agreements, milestone-based pricing, and hybrid commercial structures that align incentives between sponsors and manufacturers. Finally, a growing subset of companies is investing in sustainable manufacturing practices and circular supply chain initiatives, which signal long-term operational discipline and can influence procurement decisions among environmentally conscious sponsors.

Practical high-impact recommendations for industry leaders to fortify supply chains, accelerate technology transfer, and future-proof manufacturing operations

Leaders should prioritize a set of actionable measures that reduce risk, accelerate development timelines, and protect margins. First, diversify sourcing for critical reagents and equipment while qualifying secondary suppliers and establishing long-term contractual safeguards to mitigate tariff and supply chain disruptions. Parallel to this, invest in robust analytical capability and standardized assays to shorten qualification timelines during technology transfer and to support faster regulatory submissions.

Second, adopt modular and platform-focused process architectures that enable seamless scale transitions from clinical to commercial contexts. This includes standardizing unit operations, harmonizing documentation, and embedding digital process controls to lower variability. Third, pursue strategic partnerships that combine technical depth with commercial reach; co-locating vector production with downstream fill-and-finish or analytics can materially reduce handoff risks and improve overall program timelines.

Fourth, engage proactively with regulators earlier in development to align on comparability strategies, potency assays, and long-term safety monitoring. Fifth, enhance workforce competency through targeted upskilling programs focused on GMP best practices, advanced analytics, and equipment automation. Sixth, consider regional footprint decisions through the lens of tariff exposure, talent availability, and proximity to clinical sites. Finally, incorporate sustainability metrics into facility planning and supplier selection to reduce long-term operational risk and to meet emerging stakeholder expectations.

A transparent hybrid research approach blending primary expert interviews, capability mapping, and scenario validation to underpin strategic insights

The research underpinning these insights relied on a hybrid methodology that combined expert interviews, technology assessments, and documentary analysis. Primary inputs included structured interviews with senior manufacturing leaders, quality heads, and regulatory experts across sponsor and provider organizations, which provided granular perspectives on operational constraints and strategic priorities. These qualitative insights were triangulated with technical reviews of regulatory guidance, peer-reviewed literature, and public disclosures to validate technology trends and capability claims.

A detailed capability-mapping exercise assessed service providers across vector production, process development, GMP manufacturing, analytics, and regulatory support. Technology readiness and transferability were evaluated through criteria such as platform maturity, historical comparability studies, and demonstrated commercial-scale runs. Supply chain resilience assessments considered supplier concentration, geographic exposure, and lead-time sensitivities.

Data validation included cross-referencing interview findings with third-party technical reports and observed regulatory outcomes. Scenario-based analysis explored alternative configurations for manufacturing networks and supplier strategies under varying trade and capacity conditions. The methodology emphasized transparency and reproducibility: documentation of interview protocols, inclusion criteria for capability assessments, and the rationale for scenario parameters are available to buyers as part of the research package.

A concise concluding perspective on why manufacturing capability, regulatory alignment, and supply chain resilience will determine success in advanced therapy development

The cell and gene therapy manufacturing services sector stands at an inflection point where technical progress, regulatory evolution, and geopolitical influences collectively shape strategic choices. Providers and sponsors that build modular, analytics-driven processes and secure diversified supplier networks will be better equipped to navigate tariff-driven headwinds and regional operational complexities. Early regulatory engagement and demonstrable quality systems remain non-negotiable prerequisites for successful technology transfer and commercialization.

Organizations must balance the competing imperatives of scale, flexibility, and risk reduction. Those that opt for integrated platform strategies or targeted partnerships can shorten timelines and lower program attrition, while specialists that concentrate on niche capabilities will continue to be essential for addressing high-complexity technical challenges. Ultimately, deliberate investments in process standardization, workforce capability, and regional resilience will determine competitive positioning in a market where manufacturing excellence increasingly equals therapeutic success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of closed automated bioreactor systems for large-scale CAR-T production to enhance reproducibility
  • 5.2. Implementation of digital twin and process analytical technology for real-time monitoring of gene therapy manufacturing
  • 5.3. Expansion of decentralized manufacturing networks using modular GMP suites to accelerate regional clinical supply
  • 5.4. Standardization of raw material quality and supply chain traceability for viral vector and cell substrate components
  • 5.5. Adoption of single-use manufacturing platforms to minimize cross-contamination and improve facility flexibility
  • 5.6. Collaboration between CDMOs and academic centers for development of off-the-shelf allogeneic cell therapy pipelines
  • 5.7. Regulatory harmonization efforts addressing potency assays and comparability for advanced therapy medicinal products
  • 5.8. Investment in advanced viral vector purification technologies to increase yield and reduce downstream bottlenecks
  • 5.9. Use of AI-driven process optimization for predictive maintenance and yield improvement in cell and gene therapy manufacturing
  • 5.10. Development of cryopreservation protocols and supply chain logistics to support global distribution of living cell therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 8.1. Analytical & Quality Control Services
  • 8.2. Cell Banking Services
  • 8.3. Consulting Services
  • 8.4. Fill & Finish Services
  • 8.5. GMP Manufacturing Services
  • 8.6. Process Development Services
  • 8.7. Regulatory Support Services
  • 8.8. Supply Chain & Logistics Services
  • 8.9. Technology Transfer Services
  • 8.10. Vector Production Services

9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 9.1. Gene Editing
    • 9.1.1. CRISPR/Cas9
    • 9.1.2. Transcription Activator-Like Effector Nucleases
    • 9.1.3. Zinc Finger Nucleases
  • 9.2. Vectors
    • 9.2.1. Non-Viral Vectors
      • 9.2.1.1. Cationic Lipids
      • 9.2.1.2. Chitosan-Based Vectors
      • 9.2.1.3. Dendrimers
      • 9.2.1.4. Inorganic Nanoparticles
      • 9.2.1.5. Liposomes
      • 9.2.1.6. Naked DNA/RNA
      • 9.2.1.7. Peptide-Based Vectors
      • 9.2.1.8. Polymeric Vectors
    • 9.2.2. Viral Vectors
      • 9.2.2.1. Adeno-Associated Virus (AAV) Vectors
      • 9.2.2.2. Adenovirus Vectors
      • 9.2.2.3. Herpes Simplex Virus (HSV) Vectors
      • 9.2.2.4. Retrovirus Vectors

10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
    • 10.1.1. Coronary Artery Disease
    • 10.1.2. Heart Failure
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. HIV
  • 10.3. Monogenic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Hemophilia
    • 10.3.3. Sickle Cell Anemia
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Solid Tumors

11. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 11.1. Clinical Manufacturing
  • 11.2. Commercial Manufacturing

12. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes & Academic Institutions

13. Cell & Gene Therapy Manufacturing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Manufacturing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Manufacturing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced BioScience Laboratories, Inc. by Institut Merieux
    • 16.3.2. AGC Biologics
    • 16.3.3. AmplifyBio
    • 16.3.4. Bio-Techne Corporation
    • 16.3.5. C.H. Boehringer Sohn AG & Co. KG
    • 16.3.6. Catalent, Inc.
    • 16.3.7. Cell Therapies Pty Ltd.
    • 16.3.8. Cell-Easy
    • 16.3.9. Charles River Laboratories International, Inc.
    • 16.3.10. Danaher Corporation
    • 16.3.11. eXmoor Pharma Concepts Limited
    • 16.3.12. FUJIFILM Diosynth Biotechnologies
    • 16.3.13. Genezen Laboratories, Inc.
    • 16.3.14. Laboratory Corporation of America Holdings
    • 16.3.15. Lonza Group AG
    • 16.3.16. Merck KGaA
    • 16.3.17. Miltenyi Biotec B.V. & Co. KG
    • 16.3.18. Minaris Regenerative Medicine GmbH by Resonac Corporation
    • 16.3.19. Nikon Corporation
    • 16.3.20. Novartis AG
    • 16.3.21. Oxford Biomedica PLC
    • 16.3.22. ProPharma Group Holdings, LLC
    • 16.3.23. Recipharm AB
    • 16.3.24. Samsung Biologics Co., Ltd.
    • 16.3.25. SGS S.A.
    • 16.3.26. STEMCELL Technologies Inc.
    • 16.3.27. Takara Bio Inc.
    • 16.3.28. Thermo Fisher Scientific Inc.
    • 16.3.29. uBriGene Biosciences Inc.
    • 16.3.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZ